Henrik Zetterberg (neurochemist)

Zetterberg was born^[2] and brought up in the Gothenburg archipelago, Sweden.^[1] He completed his doctoral thesis in 2003 on the subject of the Epstein–Barr virus.^[5] He performed postdoctoral research at Harvard using zebrafish as a model for alzheimer's disease.^[6][1] Zetterberg has worked together with Kaj Blennow, whom he met during his PhD, on many projects including coleading the Clinical Neurochemistry Laboratory together with him.^[1]

His research includes the development of methods for early diagnostics for frontotemporal dementia through the use of Biomarkers,^[7] In 2020, a team of scientists led by Zetterberg published results regarding a new diagnostic for Alzheimer's disease based on protein concentrations in cerebrospinal fluid, which is a colorless fluid surrounding the brain and spinal cord. The test was reported to have an accuracy of around 90% and could detect the disease about two decades before significant symptoms were present.^[8]